Cartalax 20 mg

Cartalax is a short peptide bioregulator developed within the Khavinson school of peptide research at the Saint Petersburg Institute of Bioregulation and Gerontology. Classified as a synthetic tripeptide with the sequence Ala-Glu-Asp (AED), Cartalax was developed to investigate how minimal peptide sequences interact with cartilage tissue and connective-tissue research models. Although it shares the AED sequence with Cardiogen, within the Khavinson framework Cartalax is treated as a distinct compound with a separate tissue-selectivity profile focused on chondrocyte and connective-tissue cell systems. Its compact structure positions Cartalax as a useful research compound for studying tissue-specific peptide signaling in laboratory contexts.

At the cellular and molecular level, Cartalax is studied for its proposed ability to engage with chromatin structure and modulate transcriptional activity within chondrocytes and connective-tissue cell models. Research observations within the Khavinson framework suggest that short bioregulator peptides interact with specific DNA regions to influence the expression of genes associated with cartilage matrix organization, chondrocyte renewal, and extracellular-matrix protein synthesis in joint-derived cell systems. These observations are consistent with the broader proposition that short peptides act as gene-expression regulators within tissues from which their parent peptide complexes were originally extracted.

Research interest in Cartalax centers on cartilage-tissue gene expression studies, connective-tissue cellular research models, and extracellular-matrix investigations. Comparative work on tissue-specific bioregulators positions Cartalax alongside other connective-tissue-targeted oligopeptides used to explore peptidergic regulation of cartilage biology in cell-culture and animal research models (Khavinson V.K., Anisimov V.N., 2009, Advances in Gerontology). Additional reports within the Khavinson tradition describe how the AED sequence influences chondrocyte gene-expression profiles in cartilage research models, supporting continued laboratory investigation of Cartalax in connective-tissue and joint biology research.

The peptide is supplied as a lyophilized powder to ensure optimal stability during storage and handling.

The development of short peptide bioregulators began in the 1970s at the Military Medical Academy in Saint Petersburg, where Professor Vladimir Khavinson and colleagues isolated peptide fractions from animal tissues that appeared to restore organ-specific function in experimental models. This work led to the founding of the Saint Petersburg Institute of Bioregulation and Gerontology and the systematic study of tissue-derived peptide complexes, including the cartilage peptide complex from which Cartalax was later derived.

Cartalax was identified within this research program as a synthetic tripeptide bioregulator with the sequence Ala-Glu-Asp (AED), associated with cartilage tissue and connective-tissue research models. Although the AED sequence is shared with Cardiogen, the Khavinson framework treats these two compounds as distinct research entities with separate tissue-selectivity profiles, in line with the broader hypothesis that minimal peptide bioregulators express tissue-specific selectivity based on the parent complex from which they were originally derived. Subsequent biochemical and molecular investigations explored how Cartalax interacts with chromatin and influences chondrocyte gene expression, supporting the hypothesis that minimal peptide sequences can act as tissue-specific gene-expression modulators within cartilage and connective-tissue cell systems.

Today, Cartalax is positioned within the wider family of Khavinson-school oligopeptides studied for cartilage-tissue gene expression, connective-tissue cellular research, and extracellular-matrix research in laboratory contexts.

1. Chromatin Interaction and Chondrocyte Gene Expression

Within the Khavinson framework, Cartalax is proposed to interact with specific regions of double-stranded DNA and associated chromatin proteins, where it has been reported to influence gene-expression patterns in chondrocyte research models. This proposed mode of action positions Cartalax as a tool for investigating peptide-mediated chromatin engagement and transcriptional regulation in cartilage-derived cell systems.

2. Chondrocyte Signaling and Cartilage-Tissue Pathways

Research observations suggest that Cartalax engages with intracellular signaling pathways relevant to chondrocyte function, including pathways associated with proteoglycan and collagen synthesis research and chondrocyte renewal research models. These observations make Cartalax a useful compound for exploring tissue-specific peptide signaling in cartilage cell-culture systems.

3. Extracellular-Matrix and Connective-Tissue Research

Comparative work on short peptide bioregulators indicates that the AED sequence is associated with extracellular-matrix-related gene-expression changes in connective-tissue cell models, including studies of matrix synthesis and remodeling balance. In cartilage research models, Cartalax is investigated for its role in matrix-organization studies, structural-remodeling research, and age-related connective-tissue investigations.

4. Adaptive and Homeostatic Signaling

Khavinson-school bioregulators are described as adaptive peptide regulators that operate under physiological stress conditions. Cartalax is studied for its proposed contribution to cartilage-tissue homeostasis research, including models of age-related decline in chondrocyte signaling and oxidative or inflammatory-stress adaptation in connective-tissue cell systems.

Research Applications

Conclusion

Cartalax is a Khavinson-school short peptide bioregulator with the sequence Ala-Glu-Asp, studied for its proposed role in cartilage-tissue gene expression, chondrocyte renewal research, and extracellular-matrix research. Its compact tripeptide structure and connective-tissue positioning make Cartalax a valuable laboratory compound for exploring peptidergic regulation of gene expression in cartilage and joint research models.

Research Use Disclaimer

This product is intended for research and laboratory use only. It is designed exclusively for in vitro research purposes. All information provided is for educational and research reference only. This product is not intended for human or animal use. It is not a drug, food, or cosmetic and must not be marketed, labeled, or used as such. Use and handling are restricted to trained and qualified professionals.